Synovial sarcoma is a rare and aggressive form of sarcoma that originates from the synovial cells that line joints and ligaments. It can develop in any joint or in soft tissues, including muscles and fascia. The disease is most common in adolescents and young adults. Clinically, synovial sarcoma can manifest itself as a tumor formation, accompanied by pain and limited mobility. Often, the disease is detected at a late stage, when metastases are already present, which significantly complicates its treatment and worsens the prognosis.
History of the disease and interesting historical facts
Synovial sarcoma was first described in the late 20th century, but mental retardation and misclassification of sarcomas led to the underestimation of this pathology for many years. In the 1970s, synovial sarcomas began to be identified as a separate group, which allowed for more accurate research and refined treatment approaches. An interesting fact is that synovial sarcoma was initially known as "sarcoma-like synovial tumor" due to its similarity to other soft tissue tumors, which contributed to confusion in diagnoses. In recent decades, attention to the molecular pathology of synovial sarcoma has increased, which contributes to a better understanding of the mechanisms of its occurrence and progression.
Epidemiology
Synovial sarcoma is a relatively rare disease, with an overall incidence of approximately 1-2 cases per 1 million people per year. According to statistics, synovial sarcoma accounts for approximately 10% of all malignant soft tissue tumors. It most often occurs in adolescents and young adults aged 15 to 40 years, with men being more susceptible to this disease than women. According to clinical studies, synovial sarcoma can also develop at sites of previous injuries and after surgical interventions, which suggests a connection between the disease and mechanical factors and healing processes.
Genetic predisposition to this disease
Current research suggests that synovial sarcoma may be associated with certain genetic changes. The main chromosomal abnormalities in this disease are translocations, in particular t(18;2)(q11;q34), which leads to the formation of a chimeric gene SYT-SSX, which is a marker of synovial sarcoma. In some cases, other mutations are also detected, but the main gene involved in the pathogenesis of this disease is SYT. Patients with a family history of synovial sarcoma have a higher incidence, suggesting a possible hereditary predisposition.
Risk factors for the development of this disease
Research shows that synovial sarcoma may develop under the influence of a number of risk factors. These include:
- Previous injuries to joints or soft tissues.
- Exposure to radiation, including during treatment of other types of cancer.
- Chemicals such as asbestos or arsenic, which may increase the risk of developing sarcomas.
- Certain pre-existing medical conditions, including inherited syndromes such as Li-Fraumeni syndrome.
- Age and gender - synovial sarcoma is more common in men and young people.
Diagnosis of this disease
Diagnosis of synovial sarcoma is a complex process, starting with a clinical examination. The main symptoms of the disease are:
- Pain in the joint or soft tissue area.
- A tumor formation visible on physical examination.
- Limited mobility in the joint.
Laboratory tests may include tests for tumor markers, and radiological examinations such as X-rays, MRI, and CT scans can assess the size and extent of the tumor. Confirmation of the diagnosis often requires a biopsy of a tumor sample, which allows for histological and molecular genetic testing. The differential diagnosis may include other types of sarcomas and soft tissue tumors, requiring the use of all of the above methods in combination.
Treatment
Treatment of synovial sarcoma is based on a comprehensive approach. The main treatment methods include:
- Surgical intervention - radical resection of the tumor is the main method, especially with early diagnosis.
- Pharmacological treatment aimed at reducing postoperative recurrence using chemotherapy and radiotherapy.
- Treatment with targeted therapy and immunotherapy, which becomes relevant in later stages of the disease and when other methods are ineffective.
It is important to note that in each specific case, therapy is selected individually, taking into account the prevalence of the process, the location of the tumor and the general condition of the patient.
List of medications used to treat this disease
The following groups of drugs may be used in the treatment of synovial sarcoma:
- Chemotherapy drugs such as doxorubicin and ileplatin.
- Cytostatics used in combination with chemotherapy.
- Cardioprotectors to reduce the toxicity of chemotherapy.
- Medicines for symptomatic treatment, including analgesics.
Disease monitoring
Monitoring of synovial sarcoma includes regular oncologist examinations, radiological examinations and analysis of tumor markers to assess the dynamics of the patient's condition. The prognosis for patients depends on a number of factors, including:
- Stage of the disease at the time of diagnosis.
- Tumor size.
- Presence of metastases.
- General condition of the patient and his response to therapy.
Complications may include disease recurrence, development of metastases, and side effects from treatment such as organ toxicity.
Age-related features of the disease
Synovial sarcoma manifests itself differently depending on the age group. In children and adolescents, the tumor often occurs with an aggressive course and a high risk of relapse. Elderly patients, as a rule, have more favorable clinical outcomes, although the prevalence of this tumor in the older age group is lower. It is important to take into account age-related features in approaches to treatment and monitoring of patients with this pathology.
Questions and Answers
- What is synovial sarcoma?
Synovial sarcoma is a malignant tumor that arises from synovial cells and affects joints and soft tissues. - What are the risk factors for synovial sarcoma?
Risk factors include trauma, radiation, chemical exposure, and the presence of hereditary syndromes. - How is synovial sarcoma diagnosed?
Diagnosis is based on clinical examination, laboratory and radiological studies, and tumor biopsy. - What are the treatments for synovial sarcoma?
Treatment includes surgical resection of the tumor, chemotherapy and radiotherapy, as well as targeted and immunotherapy. - What is the prognosis for patients with synovial sarcoma?
The prognosis depends on the stage of the disease at the time of diagnosis, the size of the tumor and the general condition of the patient, as well as the effectiveness of the therapy.
